MAYO CLINIC TO BEGIN PROSPECTIVE CLINICAL STUDY WITH MEDIBIO TECHNOLOGY FOR EXPANDED MARKET OPPORTUNITIES

- Study designed to determine differential diagnosis in depression patients
- Study designed to monitor patient data following pharmacological treatment

SYDNEY, Australia and MINNEAPOLIS, Dec 15 (Bernama-GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions,  is pleased to announce the first prospective clinical trial with Mayo Clinic under a 5-year Master Clinical Trial Agreement that was signed in October of this year.  This initial study, undertakes the prospective diagnosis and longitudinal monitoring of both unipolar and bipolar depression, along with the depressive subtypes (melancholic and atypical).

http://mrem.bernama.com/viewsm.php?idm=30794